Event Brief
Jan 5, 2026 at 10:03 AM ET
GH Research Advances Psychedelic to Phase 3 Trials
By The BriefBrief
GH Research's stock surged after FDA lifted hold on its depression treatment, impacting other psychedelic biotechs.
WHO: GH Research
WHAT: Advancing psychedelic treatment to Phase 3 trials
WHEN: Jan 4, 2026 at 7:00 PM ET
WHERE: United States
WHY: FDA lifted hold on experimental treatment
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Final defendant sentenced in Zaria McKeever murder case
Zaria Mckeever
May 1, 2026 at 3:23 PM ET
Saudi Arabia delays response to UAE leaving Opec
Saudi Arabia
May 1, 2026 at 3:23 PM ET
Amazon faces months of repairs after drone strikes
Amazon
May 1, 2026 at 3:23 PM ET
Minnesota bans fake AI nudes; app makers face $500K
Minnesota
May 1, 2026 at 3:23 PM ET
Page 21435 of 21435
Same format. Every time.
Continue reading — sign in or create a free account with
